GLUKOZA 40% B. Braun 440 mg/1 mL Koncentrat za otopinu za infuziju ボスニア・ヘルツェゴビナ - クロアチア語 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glukoza 40% b. braun 440 mg/1 ml koncentrat za otopinu za infuziju

b.braun adria bh d.o.o. - glukoza - koncentrat za otopinu za infuziju - 440 mg/1 ml - 1 ml koncentrat za otopinu za infuziju sadrži: 400 mg glukoze što odgovara 440 mg glukoza monohidrata 100 ml koncentrat za otopinu za infuziju sadrži: 40 g glukoza što odgovara 44 g glukoza monohidrata

Pombiliti 欧州連合 - クロアチア語 - EMA (European Medicines Agency)

pombiliti

amicus therapeutics europe limited - cipaglucosidase alfa - vrsta ii za skladištenje glikogena - drugi gastrointestinalni trakt i metabolizam, lijekovi, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Nexviadyme 欧州連合 - クロアチア語 - EMA (European Medicines Agency)

nexviadyme

sanofi b.v. - avalglucosidase alfa - vrsta ii za skladištenje glikogena - drugi gastrointestinalni trakt i metabolizam, lijekovi, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Opfolda 欧州連合 - クロアチア語 - EMA (European Medicines Agency)

opfolda

amicus therapeutics europe limited - miglustat - vrsta ii za skladištenje glikogena - ostali prehrambeni proizvodi i proizvodi metabolizma - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Trulicity 欧州連合 - クロアチア語 - EMA (European Medicines Agency)

trulicity

eli lilly nederland b.v. - dulaglutide - dijabetes mellitus, tip 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. prema rezultatima istraživanja u vezi kombinacije, utjecaj na glikemijski kontrolu i kardiovaskularnih događaja, a u ispitivanih skupina, vidi 4. 4, 4. 5 i 5.